June 18, 2014
SymBio Pharmaceuticals Limited
Fuminori Yoshida
Representative Director
President and Chief Executive Officer

SymBio Announces Korea NDA Approval of Additional Indication for Bendamustine
Hydrochloride (SyB L-0501)

TOKYO, Japan, June 18, 2014 -- SymBio Pharmaceuticals Limited (Headquarters: Tokyo, “SymBio”)
announced that the Ministry of Food and Drug Safety (MFDS) in South Korea approved bendamustine HCI(SyB L-0501) for the treatment of patients with relapsed or refractory low-grade non-Hodgkin’s lymphoma onJune 16, 2014. Bendamustine was earlier approved by the formerly known Korea Food and Drug
Administration (KFDA) in South Korea for the treatment of chronic lymphocytic leukemia and multiple
myeloma in on May 31, 2011. Eisai Korea Inc., a subsidiary of Eisai Co., Ltd. (Headquarters: Tokyo, President& CEO: Haruo Naito), promotes the products.
In Japan, SymBio received market approval of TREAKISYM® (Bendamustine) in October, 2010 for thetreatment of patients with refractory or relapsed low grade non-Hodgkin’s lymphoma and mantle celllymphoma. In other Asian markets, Bendamustine has been approved in Hong Kong (December, 2009),
Singapore (January, 2010) and Taiwan (October, 2011) for the treatment of patients with low-grade
non-Hodgkin’s lymphoma and chronic lymphocytic leukemia.
Aspiring to be a leading oncology specialty pharma in Asia Pacific, SymBio’s business in key Asian markets
continues to expand as it nimbly develops and commercializes Bendamustine (SyB L-0501) in thehematology space to address the underserved medical needs of patients.

[Please read the following to learn more about Bendamustine Hydrochloride (SyB L-0501) andSymBio Pharmaceuticals][Contact]
Takihiro Hirasawa
CFO&CBO
TEL: 81-3-5472-1125

Note to Editors

About Bendamustine Hydrochloride (SyB L-0501)
Bendamustine was first synthesized in the early 1960s in former ‘East Germany’ by Jenapharm, and iscurrently marketed in Germany under the brand name “Levact®” as a treatment for non-Hodgkin’s lymphoma,multiple myeloma and chronic lymphocytic leukemia. Mundipharma has received market authorization in a
number of EU countries for bendamustine under the brand name “Levact®.” In the United States, the drug hasbeen approved by the U.S. Food and Drug Administration and is marketed as TREANDA® for the treatment ofchronic lymphocytic leukemia and relapsed indolent B-cell non-Hodgkin's lymphoma. SymBio
Pharmaceuticals Limited originally acquired the exclusive right from Astellas Deutschland GmbH
(Headquarters: Munich, Germany, formerly Astellas Pharma GmbH) to develop and commercialize
bendamustine in Japan (December, 2005), followed by signature of a second license agreement for theexclusive right to China/Hong Kong, Taiwan, South Korea and Singapore (March, 2007).

About SymBio Pharmaceuticals Limited
SymBio Pharmaceuticals Ltd. was established in March, 2005, by Fuminori Yoshida, who previously served
concurrently as Corporate VP of Amgen Inc. and founding President of Amgen Japan. The company’s
underlying corporate mission is “delivering hope to patients in need” as it aspires to be a leading specialty
pharmaceutical company in Asia Pacific dedicated to addressing underserved medical needs with main focus
in the areas of oncology, hematology and autoimmune disease.